{"id":"oravescent-fentanyl-citrate","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL688","moleculeType":"Small molecule","molecularWeight":"528.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fentanyl is a synthetic opioid agonist that acts primarily on mu (μ) opioid receptors in the brain and spinal cord. ORAVESCENT is a proprietary oral transmucosal formulation designed for rapid absorption through the oral mucosa, allowing faster onset of analgesia compared to conventional oral opioids. This formulation is intended for breakthrough pain management in opioid-tolerant patients.","oneSentence":"Fentanyl citrate binds to opioid receptors in the central nervous system to produce analgesia and sedation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:45.365Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breakthrough pain in opioid-tolerant cancer patients"}]},"trialDetails":[{"nctId":"NCT00343733","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain","status":"COMPLETED","sponsor":"Cephalon","startDate":"2006-08","conditions":"Pain","enrollment":120},{"nctId":"NCT00228605","phase":"PHASE3","title":"Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain","status":"COMPLETED","sponsor":"Cephalon","startDate":"2005-03","conditions":"Low Back Pain, Migraine, Diabetic Neuropathies","enrollment":500},{"nctId":"NCT00214942","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain","status":"COMPLETED","sponsor":"Cephalon","startDate":"2005-09","conditions":"Chronic Low Back Pain","enrollment":""},{"nctId":"NCT00105287","phase":"PHASE3","title":"Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients","status":"COMPLETED","sponsor":"Cephalon","startDate":"2005-01","conditions":"Pain, Cancer","enrollment":100},{"nctId":"NCT00214955","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain","status":"COMPLETED","sponsor":"Cephalon","startDate":"2005-09","conditions":"Chronic Neuropathic Pain","enrollment":120},{"nctId":"NCT00105937","phase":"PHASE3","title":"OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients","status":"COMPLETED","sponsor":"Cephalon","startDate":"2004-04","conditions":"Pain, Cancer","enrollment":300}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"LOSS OF CONSCIOUSNESS"},{"count":2,"reaction":"ACCIDENTAL OVERDOSE"},{"count":2,"reaction":"RESPIRATORY DISTRESS"},{"count":2,"reaction":"SUICIDE ATTEMPT"},{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"AMNESIA"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"ANION GAP DECREASED"},{"count":1,"reaction":"ATRIOVENTRICULAR BLOCK FIRST DEGREE"},{"count":1,"reaction":"BALANCE DISORDER"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ORAVESCENT Fentanyl Citrate","genericName":"ORAVESCENT Fentanyl Citrate","companyName":"Cephalon","companyId":"cephalon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fentanyl citrate binds to opioid receptors in the central nervous system to produce analgesia and sedation. Used for Breakthrough pain in opioid-tolerant cancer patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}